Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Human Genome Sciences has completed the enrollment and initial dosing of patients in a phase II clinical trial of its anticancer drug, HGS-ETR1, in advanced non-Hodgkin's lymphoma.
Subscribe to our email newsletter
The phase II clinical trial is a multi-center, open-label study to evaluate the efficacy, safety and tolerability of HGS-ETR1 (mapatumumab), an agonistic human monoclonal antibody to TRAIL receptor 1, in patients with relapsed or refractory non-Hodgkin’s lymphoma.
The objectives of the study are to evaluate disease activity and tumor response to HGS-ETR1 in patients with advanced non-Hodgkin’s lymphoma, to evaluate the safety and tolerability of HGS-ETR1, and to determine plasma concentrations of HGS-ETR1 for use in a population pharmacokinetic analysis.
In November 2004, Human Genome Sciences announced the completion of enrollment and initial dosing of patients in a phase II study of HGS-ETR1 in advanced non-small cell lung cancer and in February 2005, announced the completion of enrollment and initial dosing in a phase II study in advanced colorectal cancer.
The three phase II studies of HGS-ETR1 initiated to date fit into a global clinical development program through which Human Genome Sciences is evaluating the novel, genomics-derived anticancer drug’s potential for use in the treatment of specific cancers.
The company expects to have the results of all three of the phase II studies available in 2005.